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A Proposal for Early Dosing Regimens in Heart
Transplant Patients Receiving Thymoglobulin
and Calcineurin Inhibition
Markus J. Barten, MD,1 Uwe Schulz, MD,2 Andres Beiras-Fernandez, MD,3 Michael Berchtold-Herz, MD,4
Udo Boeken, MD,5 Jens Garbade, MD,6 Stephan Hirt, MD,7 Manfred Richter, MD,8 Arjang Ruhpawar, MD,9
Jan Dieter Schmitto, MD,10 Felix Schönrath, MD,11 Rene Schramm, MD,12 Martin Schweiger, MD,13
Markus Wilhelm, MD,14 and Andreas Zuckermann, MD15
There is currently no consensus regarding the dose or duration of rabbit antithymocyte globulin (rATG) induction in different
types of heart transplant patients, or the timing and intensity of initial calcineurin inhibitor (CNI) therapy in rATG-treated individ-
uals. Based on limited data and personal experience, the authors propose an approach to rATG dosing and initial CNI admin-
istration. Usually rATG is initiated immediately after exclusion of primary graft failure, although intraoperative initiation may
be appropriate in specific cases. A total rATG dose of 4.5 to 7.5 mg/kg is advisable, tailored within that range according to immu-
nologic risk and adjusted according to immune monitoring. Lower doses (eg, 3.0 mg/kg) of rATG can be used in patients at low
immunological risk, or 1.5 to 2.5mg/kg for patients with infection onmechanical circulatory support. The timing of CNI introduction
is dictated by renal recovery, varying between day 3 and day 0 after heart transplantation, and the initial target exposure is influ-
enced by immunological risk and presence of infection. Rabbit antithymocyte globulin and CNI dosing should not overlap except
in high-risk cases. There is a clear need for more studies to define the optimal dosing regimens for rATG and early CNI exposure
according to risk profile in heart transplantation.
(Transplantation Direct 2016;2: e81; doi: 10.1097/TXD.0000000000000594. Published online 20 May 2016.)
Rabbit antithymocyte globulin (rATG) is widely used forinduction therapy in adult and pediatric heart trans-
plant recipients. Despite the fact that rATG has been
available for more than 30 years, new roles are being found
for its use, for example, in supporting early minimization of
calcineurin inhibitor (CNI) exposure or to reduce the risk of
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rejection in presensitized transplant candidates.1 Two rATG
products are commercially available: Thymoglobulin and
ATG-Neovii (formerly ATG-Fresenius). Thymoglobulin is a
rabbit antihuman thymocyte immunoglobulin. ATG-Neovii
is an anti–T-lymphocyte immunoglobulin derived from rab-
bits immunized with Jurkat cells, a lymphoblastoid cell line.
The 2 products cannot be considered interchangeable, with
differing dosing regimens and evidence that they exhibit dif-
ferent hematologic profiles.2,3 Thymoglobulin is more widely
used and documented than ATG-Neovii, and “rATG” will
here refer to Thymoglobulin unless otherwise stated.
In the early 2000s, rATG (Thymoglobulin) induction regi-
mens in heart transplant patients delivered a total dose of up
to 10.5 to 15mg/kg in clinical trials4-6 but high rates of hema-
tological side effects and infectious complications prompted
substantial dose reductions since that time. By the late 2000s,
a standard rATG protocol did not usually exceed 7.5mg/kg,7–9
compatible with modern dosing in kidney transplantation.10
Currently, rATG is generally dosed according to body weight,
with caution applied if the patients weigh less than 40 kg or
more than 80 kg. Adjusting the dose according to the pharma-
codynamic response, based on CD3+ T-cell count may lower
the total dose (and drug costs) while maintaining lymphocyte
suppression,11,12 but randomized trials are lacking, and data
in heart transplants remain limited.13,14 Moreover, immuno-
logical results must be provided within 12 hours to allow ad-
justment of the following dose, which is often impractical.
There is currently no consensus, however, regarding the op-
timal dose or duration of rATG induction in heart transplant
patients, or how it should be amended according to patient's
risk profile or the type of maintenance immunosuppression
regimen. The manufacturers' guidance on dosing for rATG
provides little guidance. For Thymoglobulin, the licence states
a recommended total dose in heart transplantation ranges from
3 mg/kg to 12.5 mg/kg, given over 3 to 5 days. For ATG-
Neovii, an even wider range is included in the licensed recom-
mendations: 2 to 5 mg/kg/day for between 5 and 14 days.
We previously proposed an algorithm for the use of rATG
in heart transplant patients in a variety of circumstances, in-
cluding suggested strategies for CNI exposure in each set-
ting.15 In the current article, we have sought to develop
proposals for dosing protocols for rATG, and for CNI agents
during the first postoperativemonth, in these various situations.
Where possible, these are based on published studies, but few
well-designed trials of rATG with CNI in heart transplantation
are available. Where necessary, proposals are therefore also de-
rived from the authors' many years of clinical experience with
rATG induction. In addition, 15 heart transplant centers in
Germany, Austria, and Switzerlandwere sent a questionnaire
by the authors requesting information about current pre-
scribing practices for rATG in heart transplant recipients.
Impact of rATG Dose on Lymphocyte Count
Rabbit antithymocyte globulin contains a wide range
of T cell and other antibody specificities.16 It acts primar-
ily via T-cell depletion, with preferential recovery of
CD4+CD25highFoxp3+ regulatory T cells,17–19 but also
contains antibodies against antigens on natural killer cells,
B cells and plasma cells, and against adhesion molecules
and chemokine receptors.20 Animal data indicate that T-cell
apoptosis in peripheral blood occurs even at low concentrations
of rATG,21–23 but depletion of B cells and natural killer cells
may become relevant only at high doses.21
Evidence from animal models21 and clinical kidney trans-
plantation24,25 has demonstrated the dose dependency of
rATG-induced T-cell depletion. A prospective study of 40
kidney transplants found that a very low total dose of rATG
(1.5 mg/kg) permitted recovery of the T-cell count by month
3 posttransplant, whereas a total dose of 6.0 mg/kg sup-
pressed the count for up to 1 year compared with controls.24
For kidney transplant patients, it appears that a total dose of
6mg/kg effectively depletes lymphocytes in peripheral blood26
and may be the minimum required to prevent rejection,27,28
although lower doses have proved effective in low-risk popu-
lations.24,29 In heart transplantation, a retrospective single-
center study compared lymphocyte depletion and recovery
in 105 patients given seven 1.5-mg/kg doses of rATG (total,
10.5mg/kg) versus 39patients given 5 doses (total, 7.5mg/kg).
Lymphocyte count decreased rapidly in both groups but was
significantly higher in the lower-dose cohort during days 7 to
21, after which counts were similar to month 129 (Figure 1).
The proportion of patients reaching the target absolute lym-
phocyte count of 200 per μL was achieved by 62% and 37%
of the higher-dose and lower-dose groups, respectively, by
day 7 (P = 0.009). Studies in stem cell transplantation have
confirmed that lower total exposure to rATG is associated
with faster recovery of T-cell counts.30
The split of the rATG dose, or whether dosing is started
intraoperatively or perioperatively, does not seem to be par-
ticularly influential. Limited data with rATG in kidney
transplantation26 and with ATG-Neovii in heart transplan-
tation31 have not indicated any substantive difference in
the depletion or recovery of different T-cell subpopulations
when the majority of the total dose is given earlier (eg, in a
large initial infusion), or if a shorter dosing period is used.
In kidney transplantation, 1 randomized trial found a lower
risk of delayed graft function using intraoperative rATG
versus postoperative rATG,32 and there is some evidence
for reduced ischemia-reperfusion injury with intraoperative
rATG in liver transplant patients.33 However, there are no
published data addressing the question of whether preoper-
ative or intraoperative dosing of rATG lowers the risk for
primary graft failure after heart transplantation.
Impact of rATG Dose on Safety
The key safety concerns for lymphocyte-depleting induc-
tion are infections and malignancy. Early high-dose rATG
FIGURE 1. Change in mean absolute lymphocyte count in a retro-
spective, single-center study of heart transplant patients receiving
rATG 1.5 mg/kg for 7 days (n = 107) or 5 days (n = 39).9
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regimens (total dose, 12.5 mg/kg) in kidney transplantation
increased the risk for infections, particularly for cytomegalo-
virus (CMV) infection at a time when CMV prophylaxis was
not widely used.34,35 As would be expected, this is a dose-
dependent effect. In liver transplantation, a very high total
rATG dose of 25 mg/kg over 10 days resulted in a signifi-
cantly higher rate of fatal infections than in patients given a
more normal dose of 7.5 mg/kg (34.6% vs 15.5%,
P = 0.01).36 In a randomized trial of 80 heart transplant re-
cipients, Mattei et al37 showed a higher rate of infectious
death with rATG induction versus basiliximab when a total
rATG dose of up to 12.5 mg/kg was administered. A retro-
spective study in 40 heart transplant patients, also treated
with rATG doses of up to 12.5 mg/kg, reported a higher rate
of bacterial infections as compared with induction with the
interleukin-2 receptor antagonist daclizumab.38 Such high
doses of rATG would not now be considered advisable. Sep-
arately, it should also be noted that a warning letter was is-
sued in 2014 highlighting that basiliximab is not licensed
for use in heart transplantation.39 Daclizumab is no longer
commercially available.
A retrospective single-center analysis of 523 heart trans-
plant patients by Aliabadi et al40 analyzed infection rates in
the subgroup of patients given a total rATG dose of less than
4.5 mg/kg, 4.5 to 7.5 mg/kg, or greater than 7.5 mg/kg.
Kaplan-Meier estimates indicated the 10-year incidence of se-
vere infection to be 37%, 23%, and 45%, respectively
(P < 0.001). On multivariate analysis, the cohort given 4.5
to 7.5 mg/kg had a reduced risk of severe infection compared
with the highest-dose group (hazard ratio [HR], 1.71;
P = 0.015) as might be expected, but also compared with
the lowest-dose group (HR, 1.86; P = 0.011).40 This may
have been due to the fact that higher rates of rejection un-
der low-dose rATG necessitated intensive antirejection
therapy, or that in patients who developed infection rATG
therapy was discontinued. Cytomegalovirus infection was
estimated to occur in 20%, 23%, and 35% by year 2
(P = 0.009), with CMV disease in 5%, 6%, and 23%
(P = 0.015). Based on these data, an rATG dose in the range
of 4.5 to 7.5 mg/kg would seem to be advisable with respect
to infection risk.
Regarding malignancy, the rarity of events makes an accu-
rate assessment of the impact of specific rATG doses difficult.
In the retrospective study byAliabadi et al,40 inwhich patients
were followed up for a median of 104 months, Kaplan-Meier
estimates for freedom frommalignancy did not differ between
the 3 rATG dose groups (<4.5 mg/kg, 4.5-7.5 mg/kg, or
>7.5 mg/kg) but the time to tumor development was signifi-
cantly shorter in the high-dose cohort. A recent systematic
review concluded that the risk of posttransplant lymphopro-
liferative disease (PTLD) is not influenced by rATG dose
across all organ types or specifically in heart transplanta-
tion.41 No difference in risk was observed between a total
dose of less than 5 mg/kg or 5 to 7 mg/kg, or between less
than 7.5 mg/kg and 7.5 kg or greater.41 Use of antiviral pro-
phylaxis, however, showed a clear inverse association with
risk for PTLD, and it may be that an effect of more intensive
rATG is now less relevant in the era of widespread antiviral
administration. In children, who are at particular risk for
PTLD, there is limited evidence that additional rATG doses
are a risk factor for PTLD42 and a cautious approach with
a maximum dose of 3 to 4.5 mg/kg may be advisable.
rATG Dosing in Adults: Evidence From the Literature
Studies of rATG with immediate CNI (ie, from day 0 or
day 1 posttransplant) have tended to use higher doses of
rATG than currently, with higher rates of infection than with
interleukin-2 receptor antagonist induction37,38 (Table 1).
One interesting exception is a randomized trial by Yamani
et al,8 in which low-risk heart transplant patients received
rATG at a total dose of 6 mg/kg with immediate tacrolimus
and mycophenolate mofetil but no oral steroids, a regimen
that achieved a low rate of rejections (renal function was sim-
ilar to a standard steroid-containing regimen). Confirmatory
data are lacking.
Giving rATG induction with delayed CNI is now more
usual, as clinicians seek to preserve renal function. Goland
et al9 administered rATG at a dose of 1.5 mg/kg for 5 days
(total dose, 7.5 mg/kg) in patients at standard risk for rejec-
tion, with CNI started from day 5. The incidence of biopsy-
proven acute rejection (BPAR) was 20% at 1 year. This was
significantly more frequent than that in patients known to
be at high immunological risk, who received a relatively high
total dose of 10.5 mg/kg, but there were no infection-related
deaths in the lower-dose cohort (0/39) compared with 4 of
105 in the high-dose group. Renal data beyond week 1 were
not reported. Another retrospective analysis, using a total
rATG dose of only 4.5 mg/kg per day with cyclosporine
(CsA) started at a mean of 5.3 days posttransplant, reported
an acceptable rate of BPAR grade 3A or higher (6 episodes by
month 6 in 23 patients) in an unselected cohort of heart trans-
plant patients.7 The rate of rejection was similar to that in a
previous group of 25 patients given basiliximab induction
with CsA started early (mean, 2.2 days), but neither was cre-
atinine clearance different between the 2 groups during the
1-year follow-up.7 In kidney transplantation, studies of pa-
tients receiving CNI and steroid maintenance therapy now
tend to use a dose of approximately 6 mg/kg, with higher
doses (up to 8.75 mg/kg) in sensitized patients,43 but there
are reports of successful outcomes using lower doses (eg,
3.75 mg/kg) in low-risk44,45 or unselected46 patients.
The retrospective analysis by Aliabadi et al40 is helpful re-
garding the association between rATGdose and immunosup-
pressive efficacy in patients given delayed CNI. The mean
time to start of CsA or tacrolimus was 4.3 days and 4.9 days,
respectively. Results showed a trend to more frequent acute
rejection in unselected patients given a total dose less than
4.5 mg/kg compared with 4.5 to 7.5 mg/kg (HR, 1.98;
P = 0.057), with deaths due to rejection in 14% and 3% of
patients, respectively. There was a trend onmultivariate anal-
ysis to lower survival in the group given less than 4.5 mg/kg
versus 4.5 to 7.5 mg/kg (HR, 1.56; P = 0.081), whereas the
medium-dose and high-dose groups showed similar survival
rates (HR, 0.99 for 4.5-7.5 mg/kg vs >7.5 mg; P = 0.984).
Using a combined endpoint of death, treated rejection, or se-
vere infection, the group receiving a dose of 4.5 to 7.5 mg/kg
showed the most favorable outcome (P = 0.017). These data
suggest that a total rATG dose below 4.5 mg/kg in an unse-
lected population is inadvisable if CNI initiation is delayed.
Time to Start of CNI Therapy: Evidence
From the Literature
Studies describing outcomes in rATG-treated heart trans-
plant patients have used various criteria for CNI initiation.
The starting date for CNI therapy has been predefined for a
© 2016 Wolters Kluwer Barten et al 3
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specific day posttransplant in several reports, but without
consistency: starting dates have included day 2,47 day 2 only
if hemodynamically stable,6 day 3,48 before day 5,9,49,50 on
day 5,7 or day 7.9 Clinical triggers have also been used to deter-
mine the point ofCNI introduction (eg, decline of pretransplant
serum creatinine ≥150 μmol to <150 μmol posttransplant6 or
after hemodynamic stabilization and normalization of renal
function5). Usually, CNI therapy is started within 2 to 7 days
posttransplant (Table 2). In the recent multicenter study, Scan-
dinavian Heart Transplant Everolimus de novo Study With
Early Calcineurin Inhibitors Avoidance, in which all patients
received rATG, the study protocol stipulated that CsA could
be started according to local practice but no later than day
5. One study from 2004 only started CNI at a mean of
12 days posttransplant, triggered by serum creatinine de-
clining to less than 150 μmol in patients with pretransplant
renal impairment and achieved a low rate of BPAR 3A or
higher with a mean rATG dose of 6.1 mg/kg.6 Supporting
data with such a long delay have not been published.
Proposed rATG Dosing Strategy in Adults
Current Practice
Fifteen heart transplant centers provided information re-
garding their use of rATG. Two centers do not use rATG.
An overview of current practice at the remaining 13 centers
in terms of dosing regimens for rATG and starting times for
CNI therapy is summarized in Table 3.
Timing of rATG Introduction
In the majority of cases, rATG is initiated immediately af-
ter the transplant procedure. The first dose should be delayed
for 1 to 2 hours after return to the intensive care unit to con-
firm that there is no bleeding and that the patient is hemody-
namically stable. In cases of primary graft failure with
extracorporeal membrane oxygenation, pulmonary
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TABLE 3.
Overview of dosing regimens for rATG induction and CNI
therapy in rATG-treated heart transplant patients based
on questionnaire results
Parameter Category No. centers
Timing of rATG initiation Preoperatively 1
Intraoperatively 2
Postoperativelya 10
Not stated 1
Duration of rATG therapy, d 1 4
2-5 9
7-10 2
Total dose of rATG, mg/kg <4.5 6
4.5-7.5 7
>7.5 —
Timing of CNI initiation posttransplant, d 1-3 8b
3-5 3
7-10 3
Data are shown from 14 heart transplant centers which currently use rATG in Germany (11),
Switzerland (2) and Austria (1). Two additional centers in Germany who were sent a questionnaire
do not use rATG
a Varying between 2 and 8 to 16 hours after arrival in intensive care unit (or 6 hours after aortic
clamping).
b Including day 1 if no ATG (n = 2) or if GFR >50 mL/min (n = 1); initiation dependent on renal function
(n = 3) or fixed initiation of CsA (day 1, n =1) or tacrolimus on day 2 (n = 2) or day 3 (n = 1).
6 Transplantation DIRECT ■ 2016 www.transplantationdirect.com
hypertension should be excluded as a cause of right heart fail-
ure. If the patient does not respond to treatment for pulmo-
nary hypertension within 24 hours, rATG can be started at
a dose of 1.5mg/kg per day (2.5mg/kg per day if thrombocyte
count is high [at least >100 000 and preferably >150 000/
mm3], subsequently adjusted by thrombocyte count).
It may potentially be advantageous to start rATG intraop-
eratively in patients at high risk of primary graft failure, for
example, recipients of a heart from an expanded criteria do-
nor, presensitized patients or those with a long ischemia time
(>3-4 hours), although this has not yet been assessed clini-
cally. Beiras et al52 have recently confirmed that rATG is
not filtered out of the bloodstream during mechanical sup-
port. If rATG is started intraoperatively, a suitable protocol
would be to initiate a 12-hour infusion either before transplant
or after initiation of anesthesia (with mechanical ventilation
and hemodynamic monitoring established) and introduction
of intravenous cardiovascular lines. Thrombocyte count and
function must be monitored closely, for example, every hour
during surgery and 4 times per day afterward, requiring in-
volvement of the anesthesiologist.
Defining the rATG Dose
A total dose in the range 4.5 to 7.5 mg/kg is considered ad-
visable inmost cases. This is likely to be given over 3 to 5 days,
but can be prolonged for up to 10 days if the dose is lowered or
if administration is interrupted. An initial dose of 1.5 mg/kg is
frequently used. Dosing must be adjusted as necessary based
on hematology (see Indications to amend or stop rATG ad-
ministration below). Accordingly, for twice-daily administra-
tion blood results must be available within 12 hours.
For patients at low immunological risk, a slightly lower to-
tal dose can be used (eg, 3.0-4.5 mg/kg) (Figure 2A). For
standard-risk patients, the dose is likely to be in the range
FIGURE 2. Suggested early dosing strategies for adult heart transplant patients receiving rATG and CNI therapy. A, Low or standard immu-
nological risk patients with impaired renal function, with no pretransplant MCS or infection. B, High immunological risk patients with impaired
renal function with no pretransplant MCS or infection. High immunological risk includes pretransplant DSA, black race; postpartum females;
younger age (eg, <35 years). C, Patients onMCSwith infection and impaired renal function. Patients should remain on the anti-infective regimen
assigned pretransplant for 10 to 14 days posttransplant. Monitor closely for clinical and histological signs of rejection and increase exposure if
required. If infection clears, immunosuppression can be increased. Renal function can be regarded as impaired if estimated GFR is below 50 to
60 mL/min per 1.73 m2. Cardiorenal syndrome: type 1, abrupt worsening of cardiac function leading to acute kidney injury; type 2, chronic ab-
normalities in cardiac function causing progressive chronic kidney disease; type 3 abrupt worsening of renal function causing acute cardiac
dysfunction; type 4, chronic kidney disease contributing to decreased cardiac function, cardiac hypertrophy, and/or increased risk of adverse
cardiovascular events. DSA, donor-specific antibody.
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4.5 to 6.0 mg/kg and should not exceed 7.5 mg/kg. In some
cases, centers may apply only a single 1.5 mg/kg infusion of
rATG if the clinical situation dictates, for example, if the lym-
phocyte count is low (<200/mm3) or if adverse events develop,
but the limited literature indicates that this is inadequate to
control rejection adequately.8
In patients at high immunological risk (eg, pretransplant
donor-specific antibodies, black race, postpartum females,
younger age such as <35 years), the total rATG dose should
certainly not be less than 4.5 mg/kg (although possibly
3.5 mg/kg in children), and 6.0 to 7.5 mg/kg is likely to be
appropriate (Figure 2C).
In patients on pretransplant mechanical circulatory sup-
port (MCS) with infection, a dose between 1.5 and 2.5 mg/kg
can be considered, but rATG may not be appropriate in this
setting if the patient is extremely frail.
Caution is advised with the use of rATG in patients receiv-
ing everolimus, CNI, and steroids, based on the observation
from the A2310 study that this regimen was associated with
a higher rate of early (<3 months) infectious deaths, particu-
larly in patients on pretransplantMCS,53 indicating overimmu-
nosuppression. If rATG is used in patients given everolimus
from the time of transplant, a low rATGdose should be given
(eg, total dose 1.5 to 2.5 mg/kg).
Duration of rATG Infusion
Anecdotal evidence suggests that a short infusion period
for rATG (eg, 4-6 hours) exaggerates the risk of side effects,
such as fever and thrombocytopenia. The first dose should
be infused over no less than 6 hours, and infusion of rATG
over 8 to 12 hours is advisable especially during the early
postoperative period.
Indications to Amend or Stop rATG Administration
Rabbit antithymocyte globulin dosing should be stopped in
the event of an allergic reaction (fever, hypotension) or if there
are clinical and laboratory signs of infection or sepsis. Frequent
hematological monitoring is mandatory. Heart transplant pa-
tients are vulnerable to postoperative thrombocytopenia due
to the thrombocytopenic effects of circulatory bypass. There-
fore, particular attention must be paid to thrombocyte count.
Rabbit antithymocyte globulin dose should be lowered if the
thrombocyte count is approximately 75000/mm3, halved if
it is in the range of 50000 to 75000/mm3, and discontinued
less than 50000/mm3. If the thrombocyte count is low, CD3+
cell counts can help to inform decisions on rATG dose changes
or discontinuation. Lymphocyte and neutrophil counts must
also be taken into account and can trigger dose reductions or
withdrawal (Table 4).
Assessment of an effect on thrombocyte count can, of course,
be complicated by thrombocyte transfusions. Similarly, the
hematological effects of mycophenolate mofetil therapy also
need to be taken into account.
Premedication
Each rATG infusion should be preceded by concomitant
therapy to minimize short-term adverse events, such as fe-
ver and rash, for example, a combination of H1 and H2
blockers plus intravenous steroids, with antipyretic therapy
to prevent fever.
rATG Dosing in Children
In contrast to adult recipients, registry data show that the
majority of pediatric heart transplant patients receive induc-
tion therapy: a rate of 71%was recorded in the 2013 Interna-
tional Society for Heart and Lung Transplantation Pediatric
Heart Transplant Report.54 One reason is the widespread
practice of gradually weaning children off oral steroids to
avoid a negative impact on growth and pubertal develop-
ment, in addition to the other side effects of steroids.55 Induc-
tion therapy with rATG is universal in ABO-incompatible
heart transplantation in children,56 but cases are rare. Over-
all, experience and published data concerning the use of rATG
in pediatric patients are limited due to the low numbersworld-
wide.Most pediatric heart transplant programs perform fewer
than 5 transplants a year; of 172 centers reporting data to the
ISHLT registry in 2013, only 45 transplanted 5 or more heart
grafts in children.57
Only retrospective data are available concerning the use
of rATG in children undergoing heart transplantation
(Table 5). Total doses administered have ranged from amean
of 5.7 mg/kg58 to a median of 8 mg/kg,47 although 1 early
study included doses of 17.5 mg/kg.59 Although the use of
OKT3 induction has been linked with an increased risk for
PTLD,60 the relevance of rATG dosing in children remains
amatter for debate (see also Impact of rATGdose on safety).
The limited published evidence indicates that a maximum
dose of 7.5 mg/kg is adequate in standard risk children un-
dergoing heart transplantation with CNI-based mainte-
nance therapy.48,58
The authors adopt a similar approach to rATG dosing
for children to that used in adults. Dosing is tailored ac-
cording to whether patients are low risk or high risk (eg,
pretransplant donor-specific antibody, prior cardiac surgery,
retransplantation, MCS before transplant). The duration of
rATG infusion should be not less than 6 hours. The total dose
can be as low as 3.5 mg/kg but should not exceed 7.5 mg/kg,
and use of high rATG dosages should be avoided based on a
potential risk for PTLD. The hematological triggers for dose
modification or discontinuation used in adults also apply to
children (Table 4).
The role of rATG in neonatal heart transplantation needs
further studies and investigation.
TABLE 4.
Hematological triggers to adjust or discontinue
rATG administration
Parameter Count Action
Platelets, /mm3 a >75000 No change
~75000 Reduce dose
50000-70000 Half dose
<50000 Discontinue
Leukocytes, /mm3 >3000 No action at high levels but consider dose
reduction if 3000-5000
2000-3000 Consider half dose
<2000 Discontinue
Neutrophils, /mm3 >1000 No action
<1000 Discontinue or interrupt for 1 day and reassessb
Lymphocytes, /mm3 <100 Interrupt for 1 d and reassess
a Effect of thrombocyte transfusions should be taken into account. If platelet count is high but bleeding
occurs, consider pausing rATG administration.
b Due to risk of fungal infections.
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Proposed Early CNI Dosing Strategy in Adults
Receiving rATG Induction
Timing of CNI Introduction
The timing of CNI start and the initial dose is driven by
the patient's renal function in the immediate posttransplant
period. Although no firm threshold for impaired renal func-
tion exists, an estimated glomerular filtration rate value be-
low 50 to 60 mL/min per 1.73 m2 appears to be a relevant
cutoff. In our previous proposal for use of rATG after heart
transplantation, patients with impaired renal function were
categorized by cardiorenal syndrome type 1 or 2 (kidney
dysfunction arising from cardiac causes) or type 3 or 4 (pri-
mary kidney disease).61We recognize that it can be difficult
to distinguish between cardiorenal categories at the time of
transplant unless renal disease has been diagnosed previously
(eg, diabetic nephropathy or glomerulonephritis). Therefore,
decision-making is frequently empiric, based on the rate and
extent of renal function improvement. Where there is a
steady and marked reduction in serum creatinine in the first
1 to 2 days posttransplant, CNI can be started fromday 3on-
ward. If creatinine levels decline more slowly compared with
baseline, this suggests the presence of chronic kidney disease
unrelated to cardiac function. Here, the start of CNI can be
delayed until between day 5 and day 10 (but no later), with
less aggressive initial CNI trough concentrations.
Defining CNI Exposure
For patients at low or standard immunological risk who
have poor renal function, CNI starting doses and targets
should be reduced. A trough concentration target range of
6 to 10 ng/mL for tacrolimus, and 100 to 200 ng/mL for
CsA, appears appropriate (Figure 2A). Close monitoring
for clinical or histological signs of rejection is essential to
support individualized dosing with the aim of keeping
CNI exposure as low as possible compatible with preven-
tion of rejection. Longer-term results from the SCHEDULE
study indicate that switching from CNI therapy to everoli-
mus at 7 to 11 weeks posttransplant can improve preserva-
tion of renal function.50
For patients at high immunological risk, tacrolimus is
generally preferable to CsA, with higher target levels (ta-
crolimus, 10-15 ng/mL or CsA, 200-300 ng/mL if used)
(Figure 2B). Calcineurin inhibitor therapy should be started
by day 3, and dosing should be adjusted more aggressively
than in low-risk patients, to achieve target exposure rap-
idly. Subsequent tapering of CNI exposure is dependent
on confirmed absence of rejection or adequate immunolog-
ical activity. In high-risk patients, avoiding rejection takes
precedence over protection of renal function.
A substantial minority of patients before transplant are on
MCS with both infection and impaired renal function. This
presents the daunting challenge of balancing the need to
prevent rejection without exacerbating infection, and as a
somewhat lower priority minimizing early CNI-related
nephrotoxicity. Calcineurin inhibitor exposure must be re-
duced due to the presence of infection and is likely to resem-
ble the exposure targets used for low-risk individuals with
no infection, that is, tacrolimus 6 to 10 ng/mL and CsA
100 to 200 ng/mL (Figure 2C). Infection should be mon-
itored closely, and CNI exposure can be increased once
the infection clears. The pretransplant anti-infectiveT
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regimen should be continued for 10 to 14 days after trans-
plant, and any interactions between the anti-infectives
and immunosuppressive agents should be identified and
taken into account.
Overlapping of rATG and CNI Administration
In patients at low or standard immunological risk, the final
rATG dose should be completed before the first dose of CNI,
that is, no overlap.Generally, there should be no gap between
the 2 therapies, for example, last rATG dose started in the
morning with the first CNI dose given in the evening. For pa-
tients at high immunological risk, an overlap of up to 3 to
4 days between the end of the last rATG infusion and the first
CNI dose can be considered.
CONCLUSIONS
After our previous proposals regarding patient selection
for rATG induction after heart transplantation, we have
sought here to provide guidance on dosing protocols in par-
ticular clinical settings. It is not possible to provide firm recom-
mendations regarding rATG dosing or the optimal timing,
type, and extent of CNI exposure due to the profound short-
age of well-designed clinical trials in this area. The proposals
presented here represent the authors' best judgement accord-
ing to the available literature and personal experience. There
is a clear need for more studies, and although inevitably lim-
ited by the number of available patients, we have proposed
trials which we consider to be the most urgent to define opti-
mal treatment protocols for rATG with CNI therapy after
heart transplantation (Table 6).
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